Is There Any Risk for Metabolic Syndrome in Children and Adolescents with Psychiatric Disorders?

Basit Öğe Kaydı
dc.contributor.authorBilaç, Öznur
dc.contributor.authorTahillioğlu, Akin
dc.contributor.authorÇakır, Burak
dc.contributor.authorKavurma, Canem
dc.contributor.authorÖnder, Arif
dc.contributor.authorErcan, Eyüp Sabri
dc.date.accessioned2024-08-25T18:52:07Z
dc.date.available2024-08-25T18:52:07Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: We aimed to investigate the risk of antipsychotic drug treatment in the development of metabolic syndrome (MetS) in children and adolescents and to determine which psychiatric disorder is more associated with MetS in the pediatric population. Methods: The sample consisted of 118 children and adolescents (88 used psychotropic medication). The hemogram, fasting blood glucose, lipid profile, weight, and blood pressure levels of all the participants and information regarding medication doses of the patient group at the sixth month of the treatment process were obtained. Results: Bipolar disorder (BPD) was the only psychiatric disorder associated with MetS. Quetiapine and valproic acid were found to have increasing effects on MetS. Weight gain and the increase in systolic and diastolic blood pressure significantly increased the likelihood of MetS. Hierarchical logistic regression analyses revealed that quetiapine increased the risk of MetS through weight gain, and valproic acid increased MetS risk through systolic blood pressure. Conclusion: Especially BPD and psychotropic use in children and adolescents disrupt metabolic regulation and pose a risk for MetS. Determining the risk factors causing MetS, especially in children and adolescents, plays a significant role in preventing mortality and morbidity at advanced ages.en_US
dc.identifier.doi10.1159/000533470
dc.identifier.issn2571-726X
dc.identifier.urihttps://doi.org/10.1159/000533470
dc.identifier.urihttps://hdl.handle.net/11454/102840
dc.identifier.wosWOS:001069791400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofDubai Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectMetabolic syndromeen_US
dc.subjectWeight gainen_US
dc.subjectBlood pressureen_US
dc.subjectAntipsychoticsen_US
dc.subjectPsychiatric disorderen_US
dc.subjectBipolar disorderen_US
dc.subjectChildren and adolescentsen_US
dc.subjectQuetiapineen_US
dc.subjectValproic aciden_US
dc.subjectMajor Depressive Disorderen_US
dc.subjectAntipsychotic Medicationsen_US
dc.subjectCardiovascular-Diseaseen_US
dc.subject2nd-Generation Antipsychoticsen_US
dc.subjectNational-Healthen_US
dc.subjectAdverse Eventsen_US
dc.subjectDouble-Blinden_US
dc.subjectWeight-Gainen_US
dc.subjectSchizophreniaen_US
dc.subjectPrevalenceen_US
dc.titleIs There Any Risk for Metabolic Syndrome in Children and Adolescents with Psychiatric Disorders?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu